GlassScriptPhysician profile
Reyneiro Castro
NPI 1457496770
$7,359.03
in general payments reported to CMS, 2019-2025
30 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $544 · 2021: $1,068 · 2022: $946 · 2023: $1,073 · 2024: $1,404 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,753 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,752.74 |
| Education | $135.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,429.45 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $830.61 | 2019-2025 | Nucala, Trelegy Ellipta, Benlysta |
| Genzyme Corporation | $779.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $545.33 | 2019-2025 | Dupixent |
| Amgen INC. | $484.95 | 2021-2024 | Tezspire |
| Pfizer INC. | $460.68 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $348.01 | 2020-2024 | Takhzyro, Cuvitru |
| Leo Pharma INC. | $332.35 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $291.40 | 2020-2025 | |
| Optinose US, INC. | $235.19 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $181.78 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $176.95 | 2022-2024 | |
| Octapharma USA, INC. | $156.98 | 2019-2023 | Panzyga |
| Csl Behring | $138.41 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $128.41 | 2023 | Xpovio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $114.61 | 2022-2024 | Rinvoq |
| Genentech USA, INC. | $107.38 | 2021-2025 | Xolair |
| Shire North American Group INC | $92.89 | 2019 | |
| Grifols USA, LLC | $81.59 | 2024-2025 | Xembify |
| Pharming Healthcare, INC. | $70.90 | 2024 | Ruconest |
| Greer Laboratories, INC. | $55.43 | 2024-2025 | Palforzia, Oralair |
| Kaleo, INC. | $54.88 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $54.59 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $43.66 | 2022 | |
| Incyte Corporation | $38.87 | 2022-2024 | Opzelura |
| Ionis Pharmaceuticals, INC. | $30.82 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $29.67 | 2024 | Orladeyo |
| Uswm, LLC | $25.00 | 2021 | |
| Arcutis Biotherapeutics, INC. | $23.78 | 2025 | Zoryve |
| Alk-Abello, INC | $14.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reyneiro Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.